Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
News|Articles|June 3, 2020
- Pharmaceutical Technology\'s In the Lab eNewsletter-06-03-2020
- Volume 15
- Issue 6
New SARS-CoV-2 Molecular Quality Control
The quality control from ZeptoMetrix is formulated with purified intact viral particles that have been chemically modified to render them non-infectious and refrigerator stable.
Advertisement
On May 5, 2020, ZeptoMetrix announced its new, ready-to-use NATtrol, a SARS-CoV-2 molecular quality control for laboratory QC and test validation.
According to a company press release, the quality control is formulated with purified intact viral particles that have been chemically modified to render them non-infectious and refrigerator stable, including:
- NATtrol SARS-CoV-2 Positive Control
- Product Number: NATSARS(COV2)-ERC
Complementing the release of the positive control is a negative control formulated with human A549 cells:
- NATtrol SARS-CoV-2 Negative Control
- Product Number: NATSARS(COV2)-NEG
"Due to the unprecedented COVID-19 pandemic, we were tasked to develop and deploy reliable, user-friendly commercial solutions for ready-to-use, non-infectious SARS-CoV-2 full process molecular quality controls under accelerated timelines,” said Shawn R. Smith, president and CEO of ZeptoMetrix, in the press release. “Today, I am extremely proud to announce that ZeptoMetrix has launched such controls - containing purified intact viral particles of actual SARS-CoV-2 that provide laboratories, hospitals and research facilities with essential external run controls to help ensure the reliability of COVID-19 testing.”
Source:
Articles in this issue
over 6 years ago
Bio-Rad Launches Anti-Certolizumab Pegol Antibodiesover 6 years ago
Improved Pharma to Expand its Microscopy Servicesover 6 years ago
Good Automation Practices in the Laboratoryover 6 years ago
Contamination Drives a More Concerted Approach to Genotoxinsover 6 years ago
Testing for Nitrosamines in Pharmaceutical Drugsover 6 years ago
Avantor OmniTop Sample Tubes Offers Adjustable Volume SamplingAdvertisement
Related to this article
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
Nitrosamine Problems and Industry Solutions: PharmTech Explained
3
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
4
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
5